Cannabis Social Equity Programs in Switzerland

What people mean by 'social equity' — and why Switzerland doesn't really have it

In the United States, 'cannabis social equity' typically refers to statutory programs that give licensing preference, fee waivers, technical assistance, or community reinvestment funding to people and neighborhoods disproportionately harmed by cannabis prohibition ^[1]. Examples include Illinois's Social Equity Applicant program and New York's Conditional Adult-Use Retail Dispensary (CAURD) license ^[2].

Switzerland has no equivalent. The country has not created a commercial adult-use cannabis market, so there are no licenses to allocate on an equity basis. What exists instead is a framework for time-limited scientific pilot trials, plus a long-running debate about how to shift cannabis policy from criminal to public-health footing Strong evidence. Some of these pilots include design features — like restricting participation to existing users, subsidizing testing, or capping prices — that draw on harm-reduction and equity thinking, but they are not 'social equity programs' in the American sense.

The legal basis: Article 8b of the Narcotics Act

On 15 May 2021, the Swiss Federal Assembly amended the Narcotics Act (Betäubungsmittelgesetz, BetmG / Loi sur les stupéfiants, LStup) to add Article 8b, an 'experimentation article' allowing time-limited scientific pilot trials of restricted, non-medical cannabis use. The amendment entered into force on 15 May 2021 ^[3]. Implementing details are set out in the Verordnung über Pilotversuche nach dem Betäubungsmittelgesetz (BetmPV), in force since 15 May 2021 ^[4].

Key federal requirements under BetmPV:

• Pilots must be approved by the Federal Office of Public Health (BAG/OFSP).
• Participation is limited to adult residents of the pilot municipality who already consume cannabis.
• Products must be Swiss-grown, organic where feasible, THC content disclosed, and packaging health-warning compliant.
• Trials are capped at 5 years (with possible 2-year extension) and 5,000 participants each.
• Data collection on health, consumption patterns, and market effects is mandatory.

None of these provisions reference prior convictions, socioeconomic status, or historic harms of prohibition as eligibility or preference criteria Strong evidence.

Pilot trials in practice: Zurich, Basel, Bern, Lausanne, Geneva

As of the last verified date, active or approved pilots include:

• Basel-Stadt — 'Weed Care' (launched Jan 2023): sale of cannabis through selected pharmacies to ~370 registered participants; run with the University of Basel ^[5].
• Zurich — 'Züri Can' (launched Aug 2023): up to 2,100 participants, distributed via social clubs, pharmacies, and Drogerie Bio-Läden ^[6].
• Bern, Lucerne, Biel, Olten (SCRIPT study, from 2023): coordinated multi-city pilot.
• Lausanne — 'Cann-L' and Geneva pilots: French-speaking cantons launched or preparing trials in 2023–2024.

Some pilots incorporate equity-adjacent design choices — for example, Zurich's Züri Can includes non-profit cannabis social clubs, and pricing is set to be competitive with the illicit market to reduce financial exclusion ^[6] Weak / limited. However, none of these programs offer priority access, licenses, or reinvestment to people affected by prohibition. They are consumer-focused public-health studies, not restorative-justice mechanisms.

Expungement and prior convictions

Switzerland does not have a federal cannabis expungement program tied to pilot trials. Since 1 October 2013, adult possession of up to 10 grams of cannabis has been decriminalized and is treated as a minor infraction punishable by a CHF 100 fine under Art. 28b BetmG ^[7]. Consumption itself remains a punishable contravention. Criminal records for pre-2013 convictions are governed by ordinary rules on record deletion in the Strafregisterverordnung, not by any cannabis-specific relief Strong evidence.

Advocacy groups including Legalize it! and the Swiss cannabis industry association IG Hanf have called for both a regulated market and record relief, but as of the last verified date, no bill combining the two has advanced ^[8].

What a future Swiss regulated market might look like

A parliamentary Commission for Social Security and Health (SGK-N) sub-commission has been drafting a proposal for a fully regulated adult-use cannabis market since 2023, informed by pilot results ^[9]. Publicly available drafts and press coverage suggest the model under discussion emphasizes:

• Non-profit or cooperative distribution structures
• Youth protection and advertising bans
• State control over cultivation licensing
• Tax revenue earmarked for prevention and treatment

Whether any future law will include US-style social equity provisions — such as licensing priority for prior offenders, community reinvestment, or set-asides for small growers — is unknown No data. The Swiss policy tradition leans toward universalist public-health framing rather than group-targeted reparative programs, which may make direct import of the American model unlikely.

Not legal advice

This article is informational only and is not legal advice. Swiss cannabis law changes at both federal and cantonal levels; pilot rules differ by city. If you need to know whether a specific activity is lawful, consult a qualified Swiss attorney or the Federal Office of Public Health (BAG/OFSP). Last verified: June 2024.

Sources

How this page was made